OSD
During the technology transfer for an oral solid dose hypoglycaemia drug, it was found that the product’s inconsistent dissolution rate was hindering performance. Recipharm optimised the drug product formulation in order to ensure all batches were meeting the specified dissolution acceptance criteria to ensure consistent bioavailability and dosage.
To read our case study please complete your details below: